FDA's Woodcock To Supreme Court: Mifepristone Ruling Will Create 'Significant Chaos’

Supreme Court stays Texas district court’s order until 19 April. FDA’s deputy principal commissioner says if it goes into effect, sponsors will have to submit additional applications, prescribers may need to be recertified, and FDA will have to reinstate higher dosing regimen.